Acute Myeloid Leukemia Pipeline Drugs Assessment: Clinical Trails Analysis, Play

Posted by saikrishna on May 28th, 2018

Acute Myeloid Leukemia Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Acute Myeloid Leukemia Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Acute Myeloid Leukemia Pipeline Drugs Assessment

Overview:

Acute myeloid leukemia is a type of blood cancer,affects white blood cells. It enables progress rapidly, requires immediate treatment. Acute myeloid leukemia symptoms develop over a few weeks and become increasingly more severe. Symptoms may include tiredness, pale skin, breathlessness and unusual & frequent bleeding.

If symptoms are persisted, diagnostic tests may include blood tests, bone marrow test, lumbar puncture and sometimes genomic testing may be suggested. There is no specific cure available for acute myeloid leukemia. But it is treated by the combination of therapies that include chemotherapeutic agents, stem cell transplantation, radiation therapy and targeted therapy.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/acute-myeloid-leukemia-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:

Acute myeloid leukemia pipeline drugs are segmented based onroute of administration, trial phase,and company

By Route of Administration, acute myeloid leukemia pipeline drugs are segmented into

•          Oral
•          Parenteral
•          Others

By Trial Phase, Acute Myeloid Leukemia pipeline drugs are segmented into

•          Pre-clinical phase
•          Phase-I
•          Phase II
•          Phase-III

By Company, Acute Myeloid Leukemia pipeline drugs are segmented into

•          Cyclacel Pharmaceuticals Inc. (U.S.)
•          Johnson & Johnson Services, Inc. (U.S.)
•          Novartis AG (Switzerland)
•          H. BoehringerSohn AG &Ko. KG (Germany)